share_log

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

2022年9月13日的重要生物技术催化剂-当天结束摘要
Benzinga Real-time News ·  2022/09/13 18:46
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares traded as high as 142.3 percent, in a range of $25.01 to $29.73 on day volume of 49.46 million shares versus three months average volume of 406.52 thousand shares, closed regular trading session at $29.05. The company shares traded at $28.2, down 2.93 percent in the after-hours trading session.
Akero治疗公司纳斯达克(Sequoia Capital:AKRO)公布了来自Harmonity的TOPLINE数据,这是一项为期24周的2b期研究,评估其主导产品候选药物依夫西弗明(EFX)对肝硬变前非酒精性脂肪性肝炎(NASH)患者的疗效和安全性,该研究达到了50毫克和28毫克EFX剂量组的主要终点。Akero Treateutics的股票交易量高达142.3%,当日成交量为4,946万股,区间为25.01美元至29.73美元,而三个月平均成交量为406.52万股,常规交易时段收盘时为29.05美元。该公司股价为28.2美元,在盘后交易中下跌2.93%。
Akouos (NASDAQ:AKUS) has received clearance from the U...
阿库斯纳斯达克股票...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发